Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postural Tachycardia Syndrome (POTS)
Conditions
Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
Trial Timeline
Sep 1, 2015 → Dec 1, 2022
NCT ID
NCT02558972About Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo
Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo is a phase 2 stage product being developed by Lundbeck for Postural Tachycardia Syndrome (POTS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02558972. Target conditions include Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02558972 | Phase 2 | Terminated |
Competing Products
6 competing products in Postural Tachycardia Syndrome (POTS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| IVIG + Albumin | Grifols | Phase 1/2 | 38 |